Respiratory Syncytial Virus (RSV) Vaccine

The National Health Service (NHS) have started a new vaccination program against respiratory syncytial virus (RSV) as of September 2024. This significant advancement aims to safeguard vulnerable populations, particularly individuals aged 75 to 79 and newborns, during the upcoming winter season and throughout the entire year. RSV is a prevalent virus that can pose serious health risks; studies indicate that by the age of two, approximately 90% of children will have contracted it at least once, and most individuals will experience it multiple times over their lifetimes. The infection manifests through symptoms such as coughing, sore throat, sneezing, and nasal congestion. While RSV typically resolves on its own, it can be particularly perilous for infants, potentially resulting in bronchiolitis, which complicates their breathing. Furthermore, it poses significant risks for older adults, especially those with pre-existing heart or lung conditions, as it may lead to severe complications like pneumonia. Annually, thousands of infants and elderly individuals require hospitalization due to RSV, especially during peak winter months. The NHS and its partners are diligently preparing for the rapid deployment of the RSV vaccine, which is expected to enhance protection and potentially save countless lives. Beginning September 1, all adults reaching the age of 75 will be invited to receive the vaccine through their general practice, remaining eligible until the eve of their 80th birthday. Invitations may be distributed via letter, text, or email. A catch-up initiative will also be organized for individuals aged 75-79 as of September 1, 2024, with a goal of completing vaccinations by August 31, 2025, following the guidance of the Joint Committee on Vaccination and Immunisation.